Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200003281
Browse in-depth TOC on "Electrophysiology Market"
322 - Tables62 - Figures330 - Pages
By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community.
By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population.
By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=200003281
As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany).
Abbott (US):
Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies.
Koninklijke Philips N.V. (Netherlands)
Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes.
For more information, Inquire Now!
Related Reports:
Defibrillator Market
Cardiac Monitoring & Cardiac Rhythm Management Devices Market
Ablation Technology Market
Catheters Market
Digital X-ray Market
Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@marketsandmarkets.comVisit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/electrophysiology-market-worth-us21-72-billion-by-2030-with-11-6-cagr--marketsandmarkets-302529910.html
SOURCE MarketsandMarkets
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
Fox News
an hour ago
- Fox News
Frustrated man says pregnant sister's food habits forced him to lock up groceries
A frustrated man turned to Reddit after his pregnant sister kept eating his food without asking, leading to an outpouring of support. In a post on the popular platform, the 30-year-old man shared that his 31-year-old sister had recently left her husband and moved in with him. "I have a small apartment, but I let her move in because she had nowhere else to go and she's six months pregnant," he wrote. "I wasn't very pleased about this situation, but she is my sis, after all." At first, things were going fine – until his food started disappearing. The man wrote that he has very specific foods for his fitness goals and that his sister has been eating these — including his expensive shakes, post-run snacks and meal preps. "I'm pretty disciplined about what I eat because I am in bulk stage and hitting the gym regularly," he wrote. "I portion things, label them and plan for the entire week. But every other day something's gone. Makes me crazy." When confronted about her eating habits, the sister responded by shrugging or blaming hormones. "I asked her to replace things she finishes or at least ask before taking something. … She refuses to do anything about it," he said. When the man resorted to buying a small mini-fridge and putting it in his bedroom, the sister accused him of "treating her like a thief." "I calmly told her I was tired of my groceries disappearing and that this was the easiest way to avoid fights," he said. "Now she's sulking and has told our parents, after her failed marriage, her brother is also alienating her." "Sibling relationships are often the hardest ones we ever deal with." The man sharing his story on Reddit also reported that his mother called him and said that "pregnancy isn't easy," especially with his sister's situation. "I don't think I'm being cruel … I just want my food to be left alone. A part of me understands she is going through trouble. But at my expense?" he concluded. Commenters almost unanimously sided with the man. "Where is she going to stay once the baby is born? You have got bigger problems than groceries, if she won't even contribute to food costs," one person observed. "Tell your mother to come get your sister, so she can be sure that your sister is being taken care of," another chimed in. "Boundaries must be put in place with no apologies." California-based relationship expert Audrey Hope told Fox News Digital the central issue of the disagreement goes far beyond food. "Sibling relationships are often the hardest ones we ever deal with," she noted. "And there [may be] a primal wound that began long ago in childhood that went unnoticed and unhealed." Hope also said that the pregnant sister "was probably pampered" as a child, leading to her entitlement as an adult. "Boundaries must be put in place with no apologies," she advised. "The sibling with the apartment needs to know that he is being mistreated, and it is time to own his self-esteem and self-love and put up strong boundaries."
Yahoo
an hour ago
- Yahoo
Covid is rising. New vaccines may not be ready until mid-September.
Coronavirus infections are climbing again, marking another summer wave as children go back to school. But this uptick arrives with an added layer of uncertainty because it's unclear when and which Americans can receive updated vaccines this fall. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. Daniel R. Kuritzkes, chief of the division of infectious diseases at Brigham and Women's Hospital in Boston, said the current rise looks similar to seasonal bumps in previous years and is not driving a surge in severe illness. This is the new rhythm of covid waves. Many people are getting sick - some feeling lousy - especially after returning from vacation and conferences. Most probably won't even know it's covid because the symptoms can be indistinguishable from a cold or other respiratory bug. Yet hospitals are no longer flooded with patients because immune systems are much better trained to fight the virus five years after it arrived. But Kuritzkes and other medical and public health experts worry that delays and confusion surrounding the vaccines will limit access for those who need them the most: Adults ages 65 and older and people who have chronic conditions, weakened immune systems or are pregnant. The federal committee that would recommend the updated coronavirus vaccine is not expected to meet until at least mid-September, according to industry employees and Centers for Disease Control and Prevention officials who spoke on the condition of anonymity to share sensitive information. By that point, the summer covid wave could be over, but Americans could still get a boost of immunity ahead of an expected winter wave. Here's what to know about the latest with covid and how to protect yourself: - - - What does the data show? Several metrics tracked by the CDC show a midsummer uptick of coronavirus underway in the United States. Viral levels in wastewater started rising in late June and are considered high in the West, South and Midwest and headed that direction in the Northeast, according to Marlene Wolfe, principal investigator and co-program director of WastewaterSCAN, a private initiative that tracks municipal sewage data. The levels of virus are roughly one-third of the levels recorded a year ago, when the country was experiencing an unusually large summer covid wave. Emergency room data suggests infections are disproportionately affecting children. As of Aug. 7, coronavirus diagnoses accounted for 2.18 percent of emergency room visits among children up to age 11, the largest jump of any age group. Still, some experts caution that numbers are still very small. Aaron Milstone, a pediatric infectious-disease specialist at Johns Hopkins University School of Medicine, said most children now have some level of hybrid immunity from prior infection and vaccination. But vaccines still play a key role in giving a child's body a robust immune response, he said. 'Parents get frustrated that they get their kids the vaccine and they still contract it, but the biggest point is that they didn't die or get severe illness,' said Milstone. 'It's like wearing a seat belt. It doesn't prevent an accident, but it decreases the likelihood of dying from one.' - - - What are the latest variants? Coronavirus is always evolving to become more transmissible or adept at overcoming the frontline immune defenses that stop infections. The current predominant variant is XFG, according to CDC wastewater tracking. XFG is an offshoot of the JN.1 subvariant of omicron that became dominant in the winter of 2023-2024. The Food and Drug Administration has advised vaccine manufacturers to update their formulas to target the JN.1 lineage, specifically using the LP.8.1 strain that was dominant in the spring and is closely related to XFG. The latest variants do not appear to cause worse symptoms or have significant differences compared with its predecessors, according to Scott Roberts, an assistant professor of infectious diseases at Yale School of Medicine. - - - What's the latest with vaccines? For the coming fall season, the FDA has not yet approved an updated coronavirus vaccine. In recent years, the agency has typically signed off on an updated version by late August or early September in order for pharmacies and doctors' offices to place orders. But the agency is expected to narrow its approval for the vaccine to those 65 and older, as well as others considered at high risk for severe disease. The new approach marks a significant shift from past years when the shots have been broadly available, including to children and generally healthy adults. Once the FDA gives the greenlight, the CDC's Advisory Committee on Immunization Practices decides who should get the shots. Most insurers must pay for ACIP-recommended vaccines. Most of the newly appointed members of that committee have been critical of U.S. coronavirus vaccine policy. It's unclear whether Americans who are not considered high risk could still pay out-of-pocket to get a coronavirus vaccine off-label. That depends on the willingness of - and legal restrictions on - health care providers who would administer shots. Most Americans have at least one condition that puts them at higher risk of severe illness from covid. Physical inactivity, asthma, obesity, smoking and mood disorders are among the widespread risk factors highlighted under the new FDA framework for coronavirus vaccine approval. AHIP, the major insurance lobby, has said its members are committed to maintaining coverage of vaccines for the upcoming respiratory virus season. The FDA may not sign off on Pfizer's updated coronavirus vaccine for children between the ages of six months and 4, the company said in a statement, adding the change has nothing to do with the safety and efficacy of the shot. However, the agency recently granted full approval to Moderna's shot for young kids at risk of severe disease. The CDC stopped offering specific coronavirus vaccine guidance to pregnant women. The American College of Obstetricians and Gynecologists has strongly criticized that move, noting research has shown the virus can be dangerous for expecting mothers and cause birth complications. - - - How can I protect myself and others? Public health experts say the best way to protect yourself from covid is to stay up-to-date on vaccines. The 2024-2025 vaccine formula is still available. But it might be harder to find because some doctors and pharmacies may have decided not to restock their supplies while they wait for a new version to arrive. The CDC recommends two doses of the vaccine for people who are 65 and older or are immunocompromised. Jessica Justman, an infectious disease specialist at Columbia University, said if someone in those groups had not yet received their second dose, they should go ahead and get it now, especially if they anticipate increased exposure such as attending a large indoor gathering. The primary purpose of vaccination is to reduce the risk of severe disease, hospitalization and death. For those wanting to avoid infections completely, experts advise wearing surgical or KN95/N95 masks, avoiding crowded indoor settings and ventilating rooms. For those who get infected, the CDC guidance to resume normal activities is to wait until your symptoms are improving and you have been fever-free for 24 hours without using fever-reducing medication. Then you should take precautions for an additional five days, such as social distancing and masking. - - - Rachel Roubein and Lena H. Sun contributed to this report Related Content Ukraine scrambles to roll back Russian eastern advance as summit takes place Her dogs kept dying, and she got cancer. Then they tested her water. D.C.'s homeless begin to see the effects of Trump's crackdown Solve the daily Crossword
